Literature DB >> 32115421

The FRED for Cerebral Aneurysms of the Posterior Circulation: A Subgroup Analysis of the EuFRED Registry.

C J Griessenauer1,2, M A Möhlenbruch3, P Hendrix4, C Ulfert3, C Islak5, M Sonnberger6, T Engelhorn7, E Müller-Thies-Broussalis8, T Finkenzeller9,10, M Holtmannspötter9, J-H Buhk11, W Reith12, A Simgen12, H Janssen13, N Kocer5, M Killer-Oberpfalzer8.   

Abstract

BACKGROUND AND
PURPOSE: Flow diversion for the posterior circulation remains a promising treatment option for selected posterior circulation aneurysms. The Flow-Redirection Intraluminal Device (FRED) system has not been previously assessed in a large cohort of patients with posterior circulation aneurysms. The purpose of the present study was to assess safety and efficacy of FRED in this location.
MATERIALS AND METHODS: Consecutive patients with posterior circulation aneurysms treated at 8 centers participating in the European FRED study (EuFRED) between April 2012 and January 2019 were retrospectively reviewed. Complication and radiographic and functional outcomes were evaluated.
RESULTS: Eighty-four patients (median age, 54 years) with 84 posterior circulation aneurysms were treated with the FRED. A total of 25 aneurysms (29.8%) had previously ruptured, even though most aneurysms were diagnosed incidentally (45.2%). The intradural vertebral artery was the most common location (50%), and saccular, the most common morphology (40.5%). The median size was 7 mm. There were 8 (9.5%) symptomatic thromboembolic and no hemorrhagic complications. Thromboembolic complications occurred mostly (90.9%) in nonsaccular aneurysms. On last follow-up at a median of 24 months, 78.2% of aneurysms were completely occluded. Functional outcome at a median of 27 months was favorable in 94% of patients. All mortalities occurred in patients with acute subarachnoid hemorrhage and its sequelae.
CONCLUSIONS: The largest cohort of posterior circulation aneurysms treated with the FRED to date demonstrated favorable safety and efficacy profiles of the device for this indication. Treatment in the setting of acute subarachnoid hemorrhage was strongly related to mortality, regardless of whether procedural complications occurred.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2020        PMID: 32115421      PMCID: PMC7144644          DOI: 10.3174/ajnr.A6447

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  13 in total

1.  Risk of Branch Occlusion and Ischemic Complications with the Pipeline Embolization Device in the Treatment of Posterior Circulation Aneurysms.

Authors:  N Adeeb; C J Griessenauer; A A Dmytriw; H Shallwani; R Gupta; P M Foreman; H Shakir; J Moore; N Limbucci; S Mangiafico; A Kumar; C Michelozzi; Y Zhang; V M Pereira; C C Matouk; M R Harrigan; A H Siddiqui; E I Levy; L Renieri; T R Marotta; C Cognard; C S Ogilvy; A J Thomas
Journal:  AJNR Am J Neuroradiol       Date:  2018-06-07       Impact factor: 3.825

2.  Predictors of Incomplete Occlusion following Pipeline Embolization of Intracranial Aneurysms: Is It Less Effective in Older Patients?

Authors:  N Adeeb; J M Moore; M Wirtz; C J Griessenauer; P M Foreman; H Shallwani; R Gupta; A A Dmytriw; R Motiei-Langroudi; A Alturki; M R Harrigan; A H Siddiqui; E I Levy; A J Thomas; C S Ogilvy
Journal:  AJNR Am J Neuroradiol       Date:  2017-09-14       Impact factor: 3.825

3.  FRED Italian Registry: a multicenter experience with the flow re-direction endoluminal device for intracranial aneurysms.

Authors:  Mariangela Piano; Luca Valvassori; Emilio Lozupone; Guglielmo Pero; Luca Quilici; Edoardo Boccardi
Journal:  J Neurosurg       Date:  2019-05-10       Impact factor: 5.115

4.  Comparison of Pipeline Embolization Device and Flow Re-Direction Endoluminal Device Flow Diverters for Internal Carotid Artery Aneurysms: A Propensity Score-Matched Cohort Study.

Authors:  Christoph J Griessenauer; Ajith J Thomas; Alejandro Enriquez-Marulanda; Aviraj Deshmukh; Abhi Jain; Christopher S Ogilvy; Naci Kocer; Tobias Engelhorn; Markus Möhlenbruch; Markus Holtmannspötter; Hendrik Janssen; Thomas Finkenzeller; Wolfgang Reith; Michael Sonnberger; Jan-Hendrik Buhk; Clemens M Schirmer; Monika Killer-Oberpfalzer
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

5.  Surgical and Endovascular Comprehensive Treatment Outcomes of Unruptured Intracranial Aneurysms: Reduction of Treatment Bias.

Authors:  Christopher S Ogilvy; Noah J Jordan; Luis C Ascanio; Alejandro A Enriquez-Marulanda; Mohamed M Salem; Justin M Moore; Ajith J Thomas
Journal:  World Neurosurg       Date:  2019-03-11       Impact factor: 2.104

6.  Pipeline embolization of posterior circulation aneurysms: a multicenter study of 131 aneurysms.

Authors:  Christoph J Griessenauer; Christopher S Ogilvy; Nimer Adeeb; Adam A Dmytriw; Paul M Foreman; Hussain Shallwani; Nicola Limbucci; Salvatore Mangiafico; Ashish Kumar; Caterina Michelozzi; Timo Krings; Vitor Mendes Pereira; Charles C Matouk; Mark R Harrigan; Hakeem J Shakir; Adnan H Siddiqui; Elad I Levy; Leonardo Renieri; Thomas R Marotta; Christophe Cognard; Ajith J Thomas
Journal:  J Neurosurg       Date:  2018-05-04       Impact factor: 5.115

7.  Current Trends and Results of Endovascular Treatment of Unruptured Intracranial Aneurysms at a Single Institution in the Flow-Diverter Era.

Authors:  O Petr; W Brinjikji; H Cloft; D F Kallmes; G Lanzino
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-21       Impact factor: 3.825

8.  Meta-analysis of treatment outcomes of posterior circulation non-saccular aneurysms by flow diverters.

Authors:  Satoshi Kiyofuji; Christopher S Graffeo; Avital Perry; Mohammad Hassan Murad; Kelly D Flemming; Giuseppe Lanzino; Leonardo Rangel-Castilla; Waleed Brinjikji
Journal:  J Neurointerv Surg       Date:  2017-09-30       Impact factor: 5.836

Review 9.  Treatment of posterior circulation non-saccular aneurysms with flow diverters: a single-center experience and review of 56 patients.

Authors:  P Bhogal; M Aguilar Pérez; O Ganslandt; H Bäzner; H Henkes; S Fischer
Journal:  J Neurointerv Surg       Date:  2016-11-11       Impact factor: 5.836

Review 10.  Flow diverter treatment of posterior circulation aneurysms. A meta-analysis.

Authors:  Cheng-Bin Wang; Wen-Wen Shi; Guang-Xu Zhang; Hu-Chen Lu; Jun Ma
Journal:  Neuroradiology       Date:  2016-01-22       Impact factor: 2.804

View more
  5 in total

1.  Retrospective analysis of intracranial aneurysms after flow diverter treatment including color-coded imaging (syngo iFlow) as a predictor of aneurysm occlusion.

Authors:  Andreas Simgen; Christine Mayer; Michael Kettner; Ruben Mühl-Benninghaus; Wolfgang Reith; Umut Yilmaz
Journal:  Interv Neuroradiol       Date:  2021-06-09       Impact factor: 1.764

2.  Flared non-flow diverting ends of the FRED flow diverter for cerebral aneurysms facilitate device anchoring at the arterial bifurcation.

Authors:  Jan-Karl Burkhardt; Laura Stone McGuire; Christoph J Griessenauer
Journal:  Neuroradiol J       Date:  2021-05-04

3.  Short-segment Internal Trapping for Symptomatic Thrombosed Large Fusiform Vertebral Artery Aneurysms (Bird's Nest Trapping): A Technical Note.

Authors:  Masahiro Nishihori; Takashi Izumi; Tetsuya Tsukada; Asuka Elisabeth Kropp; Kenji Uda; Kinya Yokoyama; Yoshio Araki; Toshihiko Wakabayashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-02-26       Impact factor: 1.742

4.  Flow Redirection Endoluminal Device (FRED) with or without Adjunctive Coiling in Treatment of Very Large and Giant Cerebral Aneurysms.

Authors:  Sedat Giray Kandemirli; Feyyaz Baltacioglu; Jessica Jesser; Osman Kizilkilic; Civan Islak; Markus Möhlenbruch; Naci Kocer
Journal:  Clin Neuroradiol       Date:  2021-07-26       Impact factor: 3.649

5.  Flow redirection endoluminal device (FRED) for treatment of intracranial aneurysms: A systematic review.

Authors:  Muhammad Waqas; Rimal H Dossani; Modhi Alkhaldi; Jocelyn Neveu; Justin M Cappuzzo; Jaims Lim; Asham Khan; Victoria Lazarov; Andre Monteiro; Jason M Davies; Adnan H Siddiqui; Elad I Levy
Journal:  Interv Neuroradiol       Date:  2021-06-30       Impact factor: 1.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.